Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 174 of the 174 references it cites were found in a registry or an index.

Suicidality and Risk of Suicide—Definition, Drug Safety Concerns, and a Necessary Target for Drug Development: A Consensus Statement

Abstract

OBJECTIVE: To address issues concerning potential treatment-emergent "suicidality," a consensus conference was convened March 23-24, 2009. PARTICIPANTS: This gathering of participants from academia, government, and industry brought together experts in suicide prevention, clinical trial design, psychometrics, pharmacoepidemiology, and genetics, as well as research psychiatrists involved in studies of major depression, bipolar disorder, schizophrenia, substance abuse/dependence, and other psychiatric disorders associated with elevated suicide risk across the life cycle. The process involved reviews of the relevant literature, and a series of 6 breakout sessions focused on specific questions of interest. EVIDENCE: Each of the participants at the meeting received references relevant to the formal presentations (as well as the slides for the presentations) for their review prior to the meeting. In addition, the assessment instruments of suicidal ideation/behavior were reviewed in relationship to standard measures of validity, reliability, and clinical utility, and these findings were discussed at length in relevant breakout groups, in the final plenary session, and in the preparation of the article. Consensus and dissenting views were noted. CONSENSUS PROCESS: Discussion and questions followed each formal presentation during the plenary sessions. Approximately 6 questions per breakout group were prepared in advance by members of the Steering Committee and each breakout group chair. Consensus in the breakout groups was achieved by nominal group process. Consensus recommendations and any dissent were reviewed for each breakout group at the final plenary session. All plenary sessions were recorded and transcribed by a court stenographer. Following the transcript, with input by each of the authors, the final paper went through 14 drafts. The output of the meeting was organized into this scholarly article, which has been developed by the authors with feedback from all participants at the meeting and represents a consensus view. Any areas of disagreement have been noted. CONCLUSIONS: The term suicidality is not as clinically useful as more specific terminology (ideation, behavior, attempts, and suicide). Most participants applauded the FDA's effort to promote standard definitions and definable expectations for investigators and industry sponsors by endorsing the terminology in the Columbia Classification Algorithm of Suicide Assessment (C-CASA). Further research of available assessment instruments is needed to verify their utility, reliability, and validity in identifying suicide-associated treatment-emergent adverse effects and/or a signal of efficacy in suicide prevention trials. The FDA needs to build upon its new authority to systematically monitor postmarketing events by encouraging the development of a validated instrument for postmarketing surveillance of suicidal ideation, behavior, and risk within informative large health care-related databases in the United States and abroad. Over time, the FDA, industry, and clinical researchers should evaluate the impact of the current Agency requirement that all CNS clinical drug trials must include a C-CASA-compatible screening instrument for assessing and documenting the occurrence of treatment-emergent suicidal ideation and behavior. Finally, patients at high risk for suicide can safely be included in clinical trials, if proper precautions are followed, and they need to be included to enable premarket assessments of the risks and benefits of medications related to suicidal ideation, suicidal behavior, and suicide in such patients.

Overview

Integrity signals

Registry

Crossref · 10.4088/jcp.10cs06070blu

Cites

174 of 174 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 173 references

Cited by

See all 129

Metadata

Authors
Meyer, R. E., Salzman, C., Youngstrom, E. A., Clayton, P. J., Goodwin, F. K., Mann, J. J., Alphs, L. D., Broich, K., Goodman, W. K., Greden, J. F., Meltzer, H. Y., Normand, S.-L. T., Posner, K., Shaffer, D., Oquendo, M. A., Stanley, B., Trivedi, M. H., Turecki, G., Beasley, C. M., Beautrais, A. L., Bridge, J. A., Brown, G. K., Revicki, D. A., Ryan, N. D., & Sheehan, D. V.
Affiliations
  • Harvard University (US)
  • University of North Carolina at Chapel Hill (US)
  • American Foundation for Suicide Prevention (US)
  • George Washington University (US)
  • Columbia University (US)
  • Johnson & Johnson (United States) (US)
  • Federal Institute for Drugs and Medical Devices (DE)
  • Icahn School of Medicine at Mount Sinai (US)
  • University of Michigan (US)
  • Vanderbilt University (US)
  • The University of Texas at Dallas (US)
  • McGill University (CA)
  • Eli Lilly (United States) (US)
  • Yale University (US)
  • Nationwide Children's Hospital (US)
  • University of Pennsylvania (US)
  • United BioSource Corporation (United Kingdom) (GB)
  • University of Pittsburgh (US)
  • University of South Florida (US)
Corresponding author
Meyer, Roger E.
Venue
The Journal of Clinical Psychiatry
Published
2010-08-15
Volume
71
Issue
08
Pages
e1-e21
ISSN
0160-6689 (ISSN-L)
OpenAlex
W2074444215
Cited by
129
References
173
Citations by year
2026: 1 · 2025: 5 · 2024: 6 · 2023: 3 · 2022: 5 · 2021: 6 · 2020: 7 · 2019: 8 · 2018: 6 · 2017: 9 · 2016: 13 · 2015: 13 · 2014: 12 · 2013: 13 · 2012: 8
FWCI
12.27
Type
journal article
Language
en
Open access
closed
Locations
  • The Journal of Clinical Psychiatry (publishedVersion)
  • PubMed (publishedVersion)
  • DigitalGeorgetown (Georgetown University Library) (submittedVersion)
Funders
National Institute of Mental Health (R01MH048514)
Topics
  • Social Sciences › Psychology › Clinical Psychology › Suicide and Self-Harm Studies
  • Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
Keywords
suicidality, suicide risk, suicidal ideation, suicidal behavior, suicide attempts, suicide prevention, drug safety, adverse drug reactions, psychometric reliability and validity, post-marketing surveillance, FDA regulatory authority, psychiatric drug development, major depressive disorder, bipolar disorder, schizophrenia, substance use disorders
MeSH terms
Adolescent, Adult, Age Factors, Antidepressive Agents, Mental Disorders, Child, Clinical Trials as Topic, Consensus Statements as Topic, Major Depressive Disorder, Humans, Terminology as Topic, Psychometrics, Suicide, Suicide, Attempted, United States, United States Food and Drug Administration, Meta-Analysis as Topic, Reproducibility of Results, Randomized Controlled Trials as Topic, Risk Assessment, Drug Discovery, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Suicidality and Risk of Suicide—Definition, Drug Safety Concerns, and a Necessary Target for Drug Development: A Consensus Statement. https://app.cochat.ai/papers/10.4088/jcp.10cs06070blu
The paper
Meyer, R. E., Salzman, C., Youngstrom, E. A., Clayton, P. J., Goodwin, F. K., Mann, J. J., Alphs, L. D., Broich, K., Goodman, W. K., Greden, J. F., Meltzer, H. Y., Normand, S.-L. T., Posner, K., Shaffer, D., Oquendo, M. A., Stanley, B., Trivedi, M. H., Turecki, G., Beasley, C. M., . . . Sheehan, D. V. (2010). Suicidality and Risk of Suicide—Definition, Drug Safety Concerns, and a Necessary Target for Drug Development: A Consensus Statement. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.10cs06070blu

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.